ABSTRACT
Objective Interictal high-frequency oscillations (HFOs) are a promising neurophysiological biomarker of the epileptogenic zone (EZ). However, objective criteria for distinguishing pathological from physiological HFOs remain elusive, hindering clinical application. We investigated whether the distinct mechanisms underlying pathological and physiological HFOs are encapsulated in their signal morphology in intracranial EEG (iEEG) recordings and whether this mechanism-driven distinction could be simulated by a deep generative model.
Methods In a retrospective cohort of 185 epilepsy patients who underwent iEEG monitoring, we analyzed 686,410 HFOs across 18,265 brain contacts. To learn morphological characteristics, each event was transformed into a time-frequency plot and input into a variational autoencoder. We characterized latent space clusters containing morphologically defined putative pathological HFOs (mpHFOs) using interpretability analysis, including latent space disentanglement and time-domain perturbation.
Results mpHFOs showed strong associations with expert-defined spikes and were predominantly located within the seizure onset zone (SOZ). Discovered novel pathological features included high power in the gamma (30–80 Hz) and ripple (>80 Hz) bands centered on the event. These characteristics were consistent across multiple variables, including institution, electrode type, and patient demographics. Predicting 12-month postoperative seizure outcomes using the resection ratio of mpHFOs outperformed unclassified HFOs (F1=0.72 vs. 0.68) and matched current clinical standards using SOZ resection (F1=0.74). Combining mpHFO data with demographic and SOZ resection status further improved prediction accuracy (F1=0.83).
Interpretation Our data-driven approach yielded a novel, explainable definition of pathological HFOs, which has the potential to further enhance the clinical use of HFOs for EZ delineation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors have no conflict of interest to disclose. HN is supported by the National Institute of Neurological Disorders and Stroke (NINDS) (K23NS128318), the Sudha Neelakantan & Venky Harinarayan Charitable Fund, the Elsie and Isaac Fogelman Endowment, and the UCLA Children's Discovery and Innovation Institute (CDI) Junior Faculty Career Development Grant (#CDI-SEED-010124). AD is supported by the Uehara Memorial Foundation and the SENSHIN Medical Research Foundation. EA is supported by the National Institute of Health (R01NS064033). RS serves on scientific advisory boards and speakers bureaus and has received honoraria and funding for travel from Eisai, Greenwich Biosciences, UCB Pharma, Sunovion, Supernus, Lundbeck Pharma, Liva Nova, and West Therapeutics (advisory only); receives royalties from the publication of Pellock's Pediatric Neurology (Demos Publishing, 2016) and Epilepsy: Mechanisms, Models, and Translational Perspectives (CRC Press, 2011). RS is also supported by the Sudha Neelakantan & Venky Harinarayan Charitable Fund. RJS is supported by the NINDS R01NS106957, R01NS033310, and R01NS127524. JEJ is supported by NINDS U54NS100064 and R01NS033310. RJS and JEJ are supported by the Christina Louise George Trust. The research described was also supported by NIH/National Center for Advancing Translational Science (NCATS) UCLA CTSI Grant Number UL1TR001881.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board (IRB) at UCLA and Wayne State University gave ethical approval for the study protocol. We obtained written informed consent from patients or the guardians of pediatric patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figures 2 and 5 have been revised based on the new analysis, and supplemental information has been updated. The main text also reflects corresponding changes. Two authors (SK and CD) were added. Overall, we revised the writing to cut some redundant words.
Abbreviations
- HFOs
- high-frequency oscillations
- EEG
- electroencephalogram
- mpHFOs
- morphologically defined putative pathological HFOs
- SOZ
- seizure onset zone
- EZ
- epileptogenic zone
- iEEG
- intracranial EEG
- SEEG
- stereotactic EEG
- DL
- deep learning
- VAE
- variational autoencoder
- mArtifacts
- Artifacts defined based on morphological analysis using the VAE model
- spkHFOs
- HFOs with spikes
- non-spkHFOs
- HFOs without spikes
- HS
- hippocampal sclerosis
- FCD
- focal cortical dysplasia
- t-SNE
- t-distributed stochastic neighbor embedding
- ROIs
- regions of interest
- AUC
- area under the curve
- CT
- computed tomography
- MRI
- magnetic resonance imaging
- RMS
- root mean square
- SD
- standard deviation
- STE
- short-term energy
- IQR
- interquartile range
